# COMMITTEE OF EXPERTS ON QUALITY AND SAFETY STANDARDS IN PHARMACEUTICAL PRACTICES AND PHARMACEUTICAL CARE (CD-P-PH/PC)

Set up by the European Committee on Pharmaceuticals and Pharmaceutical Care (CD-P-PH) in accordance with Resolution CM/Res(2021)3 on intergovernmental committees and subordinate bodies, their terms of reference and working methods.

Type of committee: Subordinate body

Terms of reference valid from: 1 January 2024 until 31 December 2027, adopted by the CD-P-PH on 10th January 2024

#### PROGRAMME/SUB-PROGRAMME

PROGRAMME: Advancing social justice, good health and a sustainable environment

SUB-PROGRAMME: Quality of medicines and healthcare

# MAIN DELIVERABLES ▼

Under the authority of the CD-P-PH, the CD-P-PH/PC is instructed to complete the following deliverables, within the following deadlines:

		Deadline <b>▼</b>
1.	Draft CM Recommendation on best practices for the remote and online provision of medicines (in cooperation with the Committee of Experts on Minimising Public Health Risks Posed by Falsification of Medical Products and Similar Crimes (CD-P-PH/CMED) and Committee of Experts on the Classification of Medicines as Regards their Supply (CD-P-PH/PHO))	31/12/2024
2.	Best practices for traceability of medicines in hospital settings to minimise the occurrence of medication administration errors and ensure patient safety (in cooperation with the CD-P-PH/CMED)	31/12/2024
3.	Guidance documents on safe use of herbal products	31/12/2024
4.	Best practices on borderline products in the enforcement of medical product legislations (in cooperation with the CD-P-PH/CMED)	
5.	Mapping of hospital pharmacy practices related to the preparation of chemotherapy medicines	
6.	Guidance document for healthcare professionals on providing appropriate advice to patients undergoing cytotoxic treatment	
7.	Organisation of an event to further promote the implementation of Committee of Ministers Resolution CM/Res(2020)3 on the implementation of pharmaceutical care for the benefit of patients and health services and/or other achievements of the CD-P-PH/PC	
8.	Guidance document on providing a harmonised pharmaceutical care service in different care settings and for various target patient groups (supplementing Resolution CM/Res(2020)3 on the implementation of pharmaceutical care for the benefit of patients and health services)	
9.	Follow-up to the joint initiative with the South-eastern Europe Health Network (SEEHN) focusing on the implementation of pharmaceutical care (Resolution CM/Res(2020)3 on the implementation of pharmaceutical care for the benefit of patients and health services) in daily practice in a selected number of member States	31/12/2027

# **COMPOSITION ▼**

# Members:

Governments of the States Parties to the Convention on the Elaboration of a European Pharmacopoeia are invited to designate a representative from the relevant health authorities. The representatives may include experts responsible for the preparation and follow-up of national policies in the field of pharmaceutical practices and care. Each member of the CD-P-PH/PC shall have one vote. Where a government designates more than one member, only one of them is entitled to take part in the voting.

The sending authorities of the member States will bear the travel and subsistence expenses for their representatives' participation in the meetings of the CD-P-PH/PC. The travel and subsistence expenses of the Chair for participating in the meetings of the CD-P-PH/PC will be borne by the EDQM budget.

### Participants:

The following may send representatives, without the right to vote and at the charge of their corresponding administrative budgets:

- Parliamentary Assembly of the Council of Europe;

- Congress of Local and Regional Authorities of the Council of Europe;
- European Court of Human Rights;
- Council of Europe Commissioner for Human Rights;
- Conference of INGOs of the Council of Europe;
- Committees or other bodies of the Council of Europe engaged in related work, as appropriate.

The following may send representatives, without the right to vote and without defrayal of expenses:

- Council of Europe member States other than those mentioned above under "Members" and other States with observer status to the European Pharmacopoeia Commission;
- European Union;
- Observer States to the Council of Europe: Canada, Holy See, Japan, Mexico, United States of America;
- World Health Organization (WHO).

#### Observers:

The following may send representatives, without the right to vote and without defrayal of expenses:

- Non-member States with which the Council of Europe has a Neighbourhood Partnership including relevant cooperation activities.

Observer status may be requested in accordance with Article 8 of Resolution CM/Res(2021)3 on intergovernmental committees and subordinate bodies, their terms of reference and working methods.

#### **W**ORKING METHODS **▼**

	Plenary meetings ▼			
	Members	Meetings	Days	
2024	39	2	2	
2025	39	2	2	
2026	39	2	2	
2027	39	2	2	

Representatives taking part in the CD-P-PH/PC and, if applicable, its working groups shall complete a declaration of interest and confidentiality undertaking form.

The rules of procedure of the CD-P-PH/PC are governed by Resolution CM/Res(2021)3 on intergovernmental committees and subordinate bodies, their terms of reference and working methods.

In addition, the following provisions shall apply:

- The CD-P-PH/PC holds two regular meetings a year and carries out its programme of activities using scientific and public health oriented approaches, structured and systematic approaches for proposals for new projects and for carrying out repeated activities such as surveys.
- With a view to reaching its objectives and to enabling multidisciplinary working methods, the CD-P-PH/PC may arrange consultations, by means of hearings or by any other means, and organise conferences and seminars, as appropriate. Where necessary, in order to expedite the progress of its work, the CD-P-PH/PC may entrust a limited number of its members with a specific task.
- When appropriate, it will prioritise environmentally sound working methods, such as virtual meetings facilitated by information technology and written consultations.